BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 02/06/2016

FDA Clears Path for Triamcinolone Acetonide Injectable Suspension

The FDA has determined that Triamcinis (a triamcinolone acetonide injectable suspension) 80 mg/mL was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.

Source: Federal Register — Food and Drug AdministrationOpen original release →